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Iron chelators target both 
proliferating and quiescent  
cancer cells
Mårten Fryknäs1, Xiaonan Zhang2,3, Ulf Bremberg4, Wojciech Senkowski1, 
Maria Hägg Olofsson3, Peter Brandt5, Ingmar Persson6, Padraig D’Arcy2, Joachim Gullbo1,7, 
Peter Nygren7, Leoni Kunz Schughart8, Stig Linder2,3,* & Rolf Larsson1,*
Poorly vascularized areas of solid tumors contain quiescent cell populations that are resistant to 
cell cycle-active cancer drugs. The compound VLX600 was recently identified to target quiescent 
tumor cells and to inhibit mitochondrial respiration. We here performed gene expression analysis in 
order to characterize the cellular response to VLX600. The compound-specific signature of VLX600 
revealed a striking similarity to signatures generated by compounds known to chelate iron. Validation 
experiments including addition of ferrous and ferric iron in excess, EXAFS measurements, and structure 
activity relationship analyses showed that VLX600 chelates iron and supported the hypothesis that 
the biological effects of this compound is due to iron chelation. Compounds that chelate iron possess 
anti-cancer activity, an effect largely attributed to inhibition of ribonucleotide reductase in proliferating 
cells. Here we show that iron chelators decrease mitochondrial energy production, an effect poorly 
tolerated by metabolically stressed tumor cells. These pleiotropic features make iron chelators 
an attractive option for the treatment of solid tumors containing heterogeneous populations of 
proliferating and quiescent cells.
Iron is an essential nutrient that enables a plethora of biological processes including DNA replication and mito-
chondrial respiration. Cancer cells display increased rate of iron uptake and usage1. Thus, iron may have an 
even more fundamental role in tumor cell hemostasis than is generally appreciated. Ferrous iron is present in a 
cytoplasmic pool of soluble and chelatable iron, i.e. the labile iron pool1. Increases in the size of the labile iron 
pool has been reported to lead to increased tumor cell proliferation2. Iron is a necessary component of haem and 
iron-sulfur clusters, present in enzymes involved in oxidative phosphorylation (OXPHOS) and the Krebs cycle3. 
Iron is also required for the enzymatic activity of ribonucleotide reductase (RR), catalyzing the conversion of 
ribonucleotides to deoxyribonucleotides4. Indeed, several iron chelators have been shown to possess anti-cancer 
activity1,5–9.
We recently identified the small molecule VLX600 (Fig. 1A) as a candidate drug that preferentially targets 
quiescent cells in colon cancer 3-D multicellular tumor spheroids (MCTS)10. Similar to other compounds target-
ing quiescent cells in MCTS11,12, VLX600 affects mitochondrial function. The anti-cancer activity of VLX600 is 
attributed to the limited metabolic plasticity of cancer cells in hypoxic and nutritionally compromised environ-
ments, in which cells are unable to compensate for decreased mitochondrial OXPHOS by other means of energy 
production. This ultimately leads to a bioenergetic catastrophe and tumor cell death13.
In contrast to other agents that decrease the viability of MCTS such as nitazoxanide11, VLX600 also inhib-
its the proliferation of tumor cells in 2-D monolayer culture10. This observation prompted us to investigate the 
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molecular mechanism of action of VLX600. We here report that VLX600 binds iron and that this property is 
the underlying mechanism of the ability of VLX600 to reduce cell proliferation and to decrease mitochondrial 
OXPHOS. We show that also other iron chelators have the ability to affect the viability of MCTS, albeit with 
lower potency than VLX600. The ability of iron chelators to reduce mitochondrial energy production adds to the 
evidence of this class of compounds as having attractive anti-neoplastic activities.
Results
VLX600 is an iron chelator. The molecular structure of VLX600 is shown in Fig. 1A. The precise molecular 
mechanism of action of VLX600 was unknown and we therefore performed a Connectivity Map-based mech-
anistic exploration by examining the gene expression profile of drug-treated tumor cells14. We employed two 
different cellular models; the breast cancer cell line MCF-7 and colon carcinoma cell line HCT116, grown as 2-D 
monolayer and 3-D MCTS, respectively. MCF-7 cells were chosen since it is the most frequently used cell model 
in the Connectivity Map database. We selected MCTS HCT116 to investigate if the response is the similar when 
cells were grown in 3-D cell culture. The gene expression signature induced by VLX600 was most similar to that of 
ciclopirox olamine (CPX; 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone 2-aminoethanol), the ChemBridge 
compound 5109870 (2-hydroxy-3-methoxybenzaldehyde 2-pyridinylhydrazone), and deferoxamine (Fig. 1B). All 
of these compounds were previously described as iron chelators15–17, suggesting that the anticancer activity of 
VLX600 could be attributed to iron chelation and sequestering. Complex formation between VLX600 and differ-
ent metals was examined using spectrophotometry (Fig. 1C). VLX600 was indeed found to form complexes with 
ferrous and ferric iron as well as with Co2+, whereas only minor changes in the UV/Vis spectra were observed 
with Cu2+, Zn2+, Ni2+ or Al3+ (Fig. 1C). Addition of extracellular iron (Fe2+ and Fe3+) abolished the cytotoxic 
activity of the compound (Fig. 1D), supporting the hypothesis of iron chelation being instrumental to biological 
activity of VLX600. As previously described, VLX600 is able to reduce mitochondrial OXPHOS, particularly 
uncoupled respiration10. We found that addition of iron chloride restored OXPHOS capacity in cells exposed to 
VLX600 (Fig. 1E).
Characterization of iron chelation. By means of density functional theory (DFT) calculations on Fe(II)
(VLX600)2, the N2 nitrogen in the 1,2,4-triazine moiety was found to preferentially coordinate iron over the N4 
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Figure 1. VLX600 is an iron chelator. (A) Molecular formula for VLX600. (B) Drug-specific query 
signatures based on the 30 most up and down regulated genes in MCF-7 cells (monolayer culture) or 
HCT116 cells (multicellular spheroid culture) exposed to VLX600 were uploaded to the CMAP data base 
to identify other compounds with similar mechanism of action. (C) Analysis of metal binding by VLX600 
using spectrophotometry as described16. Note the reduction in A340 after addition of Fe2+, Fe3+ and Co2+, 
whereas Cu2+ and other metal ions do not affect A340. Representative of three independent experiments 
(D) Antiproliferative activity of VLX600 on HCT116 cells is abrogated by addition of iron chloride (FeCl2 
and FeCl3). Cells were grown for 72 h in the presence or absence of VLX600 and iron chloride and viability 
was assessed by MTT assay. Mean ± S.D. (n = 4), representative repeated experiments. (E) The reduction of 
oxygen consumption by VLX600 in HCT116 cells is reversed by the addition of iron. Mean ± S.D. (n = 4), 
representative of two independent experiments.
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nitrogen by as much as 18 kcal/mol (Fig. 2A). Using this coordination mode, the geometries were calculated for 
both oxidation states and spin states of Fe(VLX600)2 (Supplementary Table 1). Extended X-Ray Absorption Fine 
Structure (EXAFS) confirmed that iron(II) binds two VLX600 ligands to form a bis-complex where iron binds 
six nitrogen atoms in a pseudo-octahedral configuration at very short Fe-N bond distances, 1.90 and 1.915 Å 
for iron(II) and iron(III), respectively. This is in good agreement with reported iron(II)-terpyridine complexes, 
Supplementary Table 3 and the DFT calculated distances. Furthermore, Fe-C/N distances at ~2.80, 3.35 and 
4.05 Å were identified and fit with distances observed in the iron(II)-terpyridine complexes and those in the 
calculated model presented in Fig. 2A. The very short Fe-N bond distances are consistent with both iron(II) and 
iron(III) being present as low-spin complexes, and with significant back-bonding for iron(II) making the bond 
distances even shorter and the complex being significantly stabilized. The refined structure parameters are given 
in Supplementary Table 2, and the model fits of the experimental EXAFS and corresponding Fourier transforms 
(Supplementary Figures 1 and 2, respectively). The positions of the absorption edges clearly show that the VLX600 
complexes of both iron(II) and iron(III) in principle remain in their oxidation states after 48 hours of storage, see 
Figure S3. The iron(III) complex seems to be completely stable, while there is maybe a sign that the iron(II) 
complex is partly oxidized as seen in the slightly longer mean Fe-N bond distance (Supplementary Table 2), 
and the somewhat different shape of the absorption edge, see Figure S3. The pre-edge at 7111–7114 eV is a strong 
indicator of the oxidation state of iron18. However, in these cases the pre-peak is observed at 7112 eV for both 
complexes, likely due to that they are low-spin complexes and with significant back-bonding in the iron(II) 
VLX600 complex, Figure S3.
The chemical structure of VLX600 was modified by altering the position of the nitrogen in the pyridine moiety 
(VLX641 and VLX642; Fig. 2B). According to the model describing the coordination mode (Fig. 2A), this mod-
ification would result in loss of tridentate iron binding and, thus, biological activity of the molecules. Indeed, the 
VLX600 analogues showed no cytotoxic activity (Fig. 2C), suggesting limited off-target effects of the molecular 
scaffold in this biological system. Furthermore, the chemical alterations abolished the effect on mitochondrial 
respiration (Fig. 2D).
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Figure 2. Iron binding by VLX600. (A) Model for binding of VLX600 to iron generated by DFT and EXAFS. 
(B) Molecular structures of VLX600, VLX641 and VLX642. The nitrogen atom in the pyridine moiety (in red)  
is positioned in ortho- meta- and para-position, respectively. (C) Cytotoxicity was completely abrogated 
(HCT116 colon cancer cell line, FMCA, 72 hours) when the nitrogen atom in the pyridine is placed in meta- or 
para position (VLX641 and VLX642). Data is based on four independent experiments, were each concentration 
is tested in quadruplicates (mean ± S.E.M). (D) The ability of VLX600 to reduce oxygen consumption is 
dependent on the position of the nitrogen in the pyridine ring. Mean ± S.D. (n = 4), representative of three 
independent experiments.
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Inhibition of tumor cell proliferation by VLX600. VLX600 was identified in a screen for compounds 
active on 3-D tumor spheroids but also shows antiproliferative activity on colon cancer cell lines in monolayer 
culture10. We examined the effect of VLX600 on a number of colon cancer cell lines and generally found IC50 
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Figure 3. VLX600 is more potent compared to other iron chelators in reducing tumor cell proliferation. 
(A–F) Six different colon cancer cell lines (HCT116, HCT8, HT-29, RKO, DLD and SW620) were tested exposed 
to the indicated concentrations of VLX600 and viability was determined by FMCA at 72 hours. All concentrations 
tested in quadruplicate, experiments repeated three times (except HT-29, repeated twice), graphs indicate 
mean ± S.E.M. (G) Summary of IC50 concentrations from the data in (A–F). (H) VLX600 reduces DNA synthesis 
in HCT116 cells as evidenced by reduced EdU (5-ethynyl-2′ -deoxyuridine) incorporation after 24-hour treatment, 
mean + S.D., (n = 3) representative of repeated experiment. (C) VLX600 inhibits ribonucleotide reductase activity 
in vitro. Results are shown as mean + S.D. (difference significant at the level of p < 0.002). Results are expressed as 
percentage of the untreated control and shown as mean + SD from repeated experiments where each condition was 
tested in duplicate wells (n = 2).
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values in the order of 1 μ M (Fig. 3A–G). VLX600 was more potent than other iron chelators (i.e. Triapine 
(3-aminopyridine-2-carboxaldehyde-thiosemicarbazone)8, CPX, VLX5019, and deferoxamine) (Fig. 3A–G). DNA 
synthesis of colon cancer cells grown in monolayer culture was inhibited as evidenced by decreased incorporation 
of 5-ethynyl-2′-deoxyuridine (EdU) (Fig. 3H,I). The catalytic activity of ribonucleotide reductase is dependent on 
an iron-binding site in the M2 subunit of the enzyme and iron chelators have been found to inhibit this enzyme20. 
As expected, VLX600 inhibited ribonucleotide reductase activity in vitro (Fig. 3J).
Inhibition of mitochondrial activity and spheroid viability by iron chelators. We examined 
whether also other iron chelators have the ability to decrease mitochondrial oxygen consumption. Indeed, CPX, 
Triapine and deferoxamine all decreased uncoupled OXPHOS (Fig. 4A). CPX and Triapine reduced HCT116 
MCTS viability (i.e. GFP signal; previously validated to be a reliable surrogate marker of viability11), although 
with considerably lower potency compared with VLX600 (Fig. 4B). MCTS formed from HT-29 were only affected 
by VLX600 and higher concentrations of Triapine whereas deferoxamine did not show detectable activity even 
at concentrations > 300 μ M. Compound lipophilicity is particularly important for activity in MCTS systems21 
as well as in solid tumors in vivo22. The higher 3-D cytotoxic potency of VLX600 compared to other iron che-
lators examined here may at least be partially explained by the higher lipophilicity of VLX600 (XlogP ~ 3) 
(Supplementary Table 4).
Decreased hypoxia in spheroids and in tumors. The level of oxygen consumption in spheroids is 
expected to be reflected in the degree of hypoxia10. Exposure of spheroids to a mitochondrial uncoupler does 
indeed increase the pimonidazole hypoxic fraction (pHF) whereas VLX600 decreases the pHF (Fig. 5A). Similar 
to VLX600, ciclopirox reduced the pHF, albeit to lower degree than VLX600 (Fig. 5A), whereas deferoxamine 
did not cause any observable effect (Fig. 5A). These alterations of pHF are consistent with the observed degree of 
changes in MCTS viability (Fig. 4B).
A
Time (min) 
DHT-29 MCTS
EC50 concentrations in MCTS (µM)
Ciclopirox
Deferoxamine
Triapine
VLX600
16
>264
64.5
3.4
>32
>264
3.5
0.75
HCT116 HT-29
C
50
100
0.10.01 1 10 100 1000
VLX600
Triapine
Ciclopirox
Deferoxamine
HCT116 MCTS
56
24
21572 143
 FCCP
0
71
286
103
118
150
O
C
R 
(%
)
358
134
87
40
Control
Triapine
Ciclopirox
Deferoxamine
0.10.01 1 10 100
50
100
VLX600
Triapine
Ciclopirox
Deferoxamine
B
Concentration (μmol/L)
Concentration (μmol/L)
Figure 4. Iron chelators impact oxidative phosphorylation and cell viability. (A) Iron chelators diminish 
respiratory reserve capacity in monolayer cell cultures. Shown are Seahorse recordings of oxygen consumption 
of HCT116 cells exposed to the different compounds shown. Samples were run in quadruplicates, all 3 iron 
chelators tested induced a lower level of uncoupled respiration (p < 0.005 for Triapine and ciclopirox; p < 0.0005 
for deferoxamine). Chelators were added to the culture medium at the beginning of the experiment (0 minutes). 
Mean ± S.D. (n = 4), representative of three independent experiments. (B,C) HCT116 MCTS and HT-29 MCTS 
were treated with different iron chelators, and GFP fluorescence was used as a surrogate marker of viability, 
96-hours treatment. Mean ± S.D. (n = 6), representative of repeated experiment. (D) Summary of effective 
concentrations 50 (EC50) from the data in B,C.
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Figure 5. Effect of VLX600 on hypoxia and cytochrome oxidase activity. (A) VLX600 and ciclopirox, but not 
deferoxamine, reduces MCTS hypoxia. Spheroids (HCT116) were exposed to vehicle (DMSO), 6 μ M VLX600, 
6 μ M deferoxamine or 6 μ M ciclopirox. Spheroids were treated with pimonidazole for 1 h prior to fixation, 
sectioned and stained pimonidazole adducts to detect hypoxia. (B) VLX600 reduces hypoxia in vivo. HCT116 
tumors in SCID mice were allowed to grow to a size of 200 mm3 before mice were injected with VLX600. 
Pimonidazole was injected after 3 hours and the animals sacrificed after 4 hours. Tumors were sectioned and 
stained for pimonidazole adducts. (C) Quantification of pimonidazole hypoxic fraction in the experiment. 
The pimonidazole hypoxic fraction (pHF) was determined in each section and shown as average + S.D. 
(statistics by t-test, p < 0.01). (D) Determination of COXIV activity in freeze fractions using histochemistry 
and COXIV protein levels using immunohistochemistry in control and VLX600-treated MTCS. Na-azide 
(2 mM) was added to the histochemistry reaction as a specificity control where indicated. (E) COXIV activity 
in MTCS core regions (the same sections shown in (D) are here shown at higher magnification. (F) Ki67 
immunohistochemistry of HCT116 spheroids (included as reference to illustrate quiescence of cells in MCTS 
core areas).
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VLX600 is well tolerated by rodents and shows anti-tumor activity in animal tumor models which are asso-
ciated with decreased proliferative indices10. To address the question whether VLX600 affects tumor hypoxia 
in vivo, we injected VLX600 into mice bearing HCT116 colon cancer xenografts. VLX600 exposure significantly 
reduced the pHF 4 hours after injection of the drug (Fig. 5B,C).
VLX600 decreases cytochrome oxidase activity in spheroids. We and others have hypothesized 
that energy production in tumor cells situated in the deep tumor parenchyma is vulnerable and cannot tolerate 
even limited decreases in OXPHOS10–13. OXPHOS is known to be functional at oxygen concentrations as low as 
0.5%23 but it is not known whether electron transport components are expressed in core regions of spheroids. 
Cytochrome oxidase (complex IV) is rate-limiting in the electron transport chain24 and its activity was reported 
to decrease under hypoxic/hypoglycemic conditions25. We examined the distribution of cytochrome oxidase 
IV (COXIV) immunoreactivity and cytochrome oxidase in situ activity in colon cancer spheroids (Fig. 5D). 
Immunoreactivity and enzymatic reactivity were strongest in the area of 50–100 μ m from the spheroid surface 
containing Ki67-positive, proliferating cells (Fig. 5D). However, COXIV activity was clearly discerned in the core 
regions of the spheroids (Fig. 5D,E). Exposure to VLX600 for 24 hours led to a uniform reduction of cytochrome 
oxidase activity in MCTS and also to a decreased immunoreactivity for COXIV (Fig. 5D).
Discussion
The cells in the cores of MCTS have the ability to regrow after cytotoxic therapy26 and have in this respect similar-
ities to cancer initiating stem cells. Recently, several studies have identified inhibition of mitochondrial OXPHOS 
as a promising strategy to combat quiescent cancer cells in hypoxic and nutritionally compromised environ-
ments10,11,27–29. There is a growing body of observational evidence to support this idea. Importantly, and contrary 
to the Warburg hypothesis, mitochondria are the main source of ATP production in cancer cells30 and OXPHOS 
is the predominant source of ATP in also hypoxic layers of MTCS31. Furthermore, increased OXPHOS activity is 
observed in human tumors in situ compared with adjacent normal tissue32. Components involved in mitochon-
drial biogenesis, mitochondrial translation and mitochondrial lipid biosynthesis are transcriptionally upregulated 
in human breast cancer epithelial cells and downregulated in adjacent stromal cells33. Elevated expression of the 
mitochondrial markers such as TIMM17A and TOMM34 is associated with poor clinical outcome and may be 
predictive of higher tumor grade and metastasis34–36.
Mitochondrial inhibitors have long been reported to possess anti-tumor activity37–39. Examples of such com-
pounds are Rho12337, which inhibits OXPHOS40, and mitochondria-targeted lipophilic cations41. Metformin is a 
commonly prescribed anti-diabetic drug that increases cellular glucose uptake42. Metformin inhibits mitochon-
drial OXPHOS, likely through inhibition of complex I activity43,44 and metformin exposure appears to diminish 
tumor formation in diabetic patients45 and in mouse animal models46,47. VLX600 is a mild inhibitor of OXPHOS, 
primarily inhibiting uncoupled respiration (i.e total respiratory capacity)10. It is interesting to note that the limited 
effect on OXPHOS elicited by VLX600 on monolayer cultures is associated with major effects on hypoxia in sphe-
roids. A possible explanation for this phenomenon is that total available, albeit limited, mitochondria capacity 
is utilized in the cells of the core area, and that mild inhibition has large consequences in oxygen utilization and 
energy production.
Iron chelators have complex effects on tumor cells1,5–9. Inhibition of ribonucleotide reductase results in inhi-
bition of cell proliferation by depleting deoxyribonucleotide pools and we here show that iron chelators affect 
OXPHOS. We previously reported that VLX600 induces HIF-1α expression10, an observation explained by 
the present finding that the drug chelates iron. Prolyl hydroxylases, that negatively regulates HIF-1α protein 
stability, are iron-dependent enzymes48 and iron chelators are known to induce HIF-1α 49 VLX600 induces a 
HIF-1α -dependent shift to glycolysis in exposed cells10, and it is possible that this leads to further depletion of 
glucose in tumors and a strengthened bioenergetic catastrophe. Some iron chelators form redox-active complexes 
with metals, notably cupper, and this has been reported to be essential for their ability to induce apoptosis50. 
Hovever, exposure to VLX600 does not result in the generation of increased levels of reactive oxygen species in 
cells10, and the antiproliferative effects of this drug is therefore most likely due to depletion of cellular labile iron 
pools.
The ability of iron chelators to inhibit the proliferation and decrease the viability of heterogeneous populations 
of tumor cells in solid tumors opens interesting possibilities for future therapies. VLX600 is presently in a phase-I 
clinical trial (ClinicalTrials.gov NCT02222363) for patients with refractory advanced solid tumors which will 
hopefully provide proof of concept for this treatment strategy.
Experimental procedures
Cell culture. HCT116, HT-29, SW620, HT8, DLD, RKO and MCF-7 were obtained from the American Type 
Culture Collection, Manassas, VA, USA). HCT116 GFP and HT-29 GFP (human epithelial colon carcinoma 
cell lines constitutively expressing green fluorescent protein) were purchased from Anticancer Inc. (San Diego, 
CA, USA). All cell lines were sub-cultivated and grown in supplemented medium as recommended by the pro-
viders. The cell banks performed authentications by short tandem repeat analysis. No further authentication 
was performed in our laboratory. All experiments with purchased cell lines were performed within 6 months 
after resuscitation. Cells were cultured in McCoy’s 5A Modified Medium (Sigma-Aldrich) + v/v 10% inactivated 
fetal calf serum, antibiotics (streptomycin 50 μ g/mL and penicillin 60 μ g/mL) and 2 mmol/L L-glutamine at 
37 °C in 5% CO2. MCF-7 cells were maintained in Minimum Essential Medium Eagle (M5650, Sigma-Aldrich, 
Stockholm, Sweden), supplemented with 10% heat-inactivated FCS (Sigma-Aldrich, Stockholm, Sweden), 
2 mmol/L L-glutamine, 100 μ g/mL streptomycin, 100 U/mL penicillin (Sigma-Aldrich, Stockholm, Sweden) and 
1 mM sodium pyruvate (P5280, Sigma-Aldrich, Stockholm, Sweden).
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Compounds.  VLX600, VLX641 and VLX642 were were acquired from OnTarget Chemistry (Uppsala, 
Sweden). Deferoxamine, ciclopirox and triapine were from Sigma-Aldrich (St. Louis, MO, USA). For iron chela-
tion experiments, Cu2+, Co2+, Al3+, Ni2+, Zn2+ (nitrate salts) and FeCl2 and FeCl3 were obtained from Sigma 
Aldrich (St Louis, MO, USA).
Connectivity Map. The Connectivity Map (CMAP) (www.broad.mit.edu/cmap) build 02 contains 
genome-wide expression data for 1300 compounds (6100 instances, including replicates, different doses and cell 
lines). We followed the original protocol using MCF-7 breast cancer cells as described by Lamb et al.14. Briefly, 
cells were plated in 6-well plates at a density of 0.4 × 106 cells per well and were left to attach for 24 h prior to 
addition of drugs. We also performed CMAP-based mechanistic exploration in MCTS HCT116. MCTS HCT116 
were grown as previously described10 and were exposed to VLX600 (10 μ M) or to vehicle control (DMSO). 
After 6 hours treatment, the cells were washed with PBS and total RNA was prepared using RNeasy miniprep kit 
(Qiagen, Chatsworth, CA). Starting from two micrograms of total RNA, gene expression analysis was performed 
using Genome U133 Plus 2.0 Arrays according to the GeneChip Expression Analysis Technical Manual (Rev. 
5, Affymetrix Inc., Santa Clara, CA). Raw data was normalized with MAS5 (Affymetrix) and gene expression 
ratios for drug treated vs. vehicle control cells were calculated to generate lists of regulated genes. Filter criteria 
were present calls for all genes in both the VLX600 treated DMSO (vehicle) exposed control cells and an expres-
sion cut-off of at least 200 arbitrary expression units. Only probes present on HG U133A were used, for CMAP 
compatibility. The 30 most up and down regulated genes (i.e., probes) for each compound were uploaded into 
CMAP and compared to the 6100 instances in the CMAP database, to retrieve a ranked compound list. Raw and 
normalized expression data have been deposited at Gene Expression Omnibus with accession number GSE84051 
(MCF-7) and GSE53777 (MCTS HCT116).
Metal chelation analysis. 10 μ M different metals (Cu2+, Co2+, Al3+, Ni2+, Zn2+, Fe2+ and Fe3+) were sep-
arately mixed with 10 μ M VLX600. Absorbance spectra over the range 210–550 nm were obtained on Nanodrop 
ND-1000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA USA). The maximum absorption wave-
length of VLX600 is 340 nm.
Cytotoxicity assay. The Fluorometric Microculture Cytotoxicity Assay, FMCA, described in detail previously51, 
was used for measurement of the cytotoxic effect of library compounds and the established standard drugs. The 
FMCA is based on measurement of fluorescence generated from hydrolysis of fluorescein diacetate (FDA) to 
fluorescein by cells with intact plasma membranes. Cells were seeded in the drug-prepared 384-well plates using 
the pipetting robot Precision 2000 (Bio-Tek Instruments Inc., Winooski, VT). In each plate, two columns without 
drugs served as controls and one column with medium only served as blank. Cell viability was also monitored 
using the MTT assay52 (in Fig. 1D).
Spheroid viability assay. The spheroid-based cytotoxicity assay was performed as described previously11, 
with minor modifications. Briefly, 5,000 HCT116 GFP cells or 5,000 HT-29 GFP cells were seeded in 50 μ L of 
McCoy’s 5A medium (10% FBS, 2 mM glutamine, 50 μ g/mL streptomycin, 60 μ g/mL penicillin) into each well 
of 384-well U-bottom Ultra Low Attachment plates (Corning, NY). After seeding, plates were centrifuged at 
1,000 rpm for 5 minutes. Subsequently, spheroids were grown for 7 days without medium change in 37 °C, 5% 
CO2. Then, drugs were administered using Echo Liquid Handler 550 (Labcyte, Sunnyvale, CA). After 96 h of 
drug incubation, mean spheroid GFP fluorescence was measured using ArrayScan VTI Reader (Cellomics Inc., 
Pittsburgh, PA, USA).
Ribonucleotide reductase assay. Ten million (1 × 107) HCT116 cells grown in 150 mm plates were 
exposed to indicated drugs for 24 hours. The ribonucleotide assay was performed as previously described19.
Immunohistochemistry. Multicellular spheroids produced by the hanging drop method in 96 well plates 
were fixed in 2% buffered formalin, dehydrated, embedded in paraffin and sectioned. Each sample contained 
24 spheroids (spheroids from each 96 well plate were pooled into 4 groups). The sections were deparaffinized 
with xylene, rehydrated and microwaved and then incubated overnight with the monoclonal primary antibodies 
diluted in 1% (wt/vol) bovine serum albumin and visualized by standard avidin–biotin–peroxidase complex tech-
nique (Vector Laboratories, Burlingame, CA, USA). Counterstaining was performed with Mayer’s haematoxylin. 
Antibody MIB-1 (against the nuclear proliferation-associated antigen Ki67) was from Immunotech SA, Marseille, 
France and used at a dilution 1:400.
LogP predictions. XlogP3 values were retrieved from Pub Chem https://pubchem.ncbi.nlm.nih.gov/
compound/.
Assessment of cellular DNA synthesis. The fluorescence microscope ArrayScan V HCS system 
(Cellomics Inc.) was used for measurement of 5-ethynyl-2′-deoxyuridine (EdU) incorporation. HCT116 cells 
were seeded into 96-well plates (PerkinElmer Inc., Wellesley, MA, USA), left to attach over night, before test com-
pounds were added. Cells were treated with VLX600 for 24 h or vehicle control. Cells were stained using Click-iT 
EdU HCS assay (C10354, Invitrogen, Molecular Probes Inc., OR, USA) according to the manufacturer’s instruc-
tions. Processed plates were loaded in the ArrayScan and analyzed. Images were acquired for each fluorescence 
channel, using suitable filters with 10x objective and in each well at least 1,000 cells were analyzed. Average total 
intensity in the EdU channel was measured.
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Measurement of oxygen consumption rates (OCR). Measurements of cellular oxygen consumption 
were performed using a Seahorse XF analyzer as recommended by the manufacturer (Agilent Technologies, Santa 
Clara, CA). Briefly, cells were pleated in 100 μ L culture medium in XF 24-well cell plates with indicated blank 
control wells. Plates were first placed at room temperate for 1 hour and then moved to an incubator for another 
1–5 hours to facilitate attachment of cells. Another 150 μ l of culture medium was then added to each well followed 
by overnight incubation. Before the OCR measurements, medium was removed from each well and replaced with 
500 μ L Seahorse assay media (pyruvate 1 mM, glucose 25 mM) at 37 °C without CO2 for 1 h. OCR were measured 
using an XF24 Extracellular Flux Analyzer. A cell mitochondrial stress kit from Seahorse Bioscience was used for 
mitochondrial stress tests and experiments were performed as described previously10.
Assessment of pimonidazole adducts accumulation in mouse xenografts. Once HCT116 tumors 
in SCID mice had grown to a size of 200 mm3, mice were injected with VLX600. Pimonidazole was injected 1 hour 
before the animals were sacrificed. Tumors were sectioned and stained for pimonidazole adducts. Quantification 
was performed double blind from photographs of the stained slides.
Computational Details. All density functional calculations were done using Jaguar 8.553 (Schrodinger, 
Inc., New York, NY, 2014). Structures were optimized using the LACVP* basis set54 and the M06 functional55. 
Single-point energy calculations were performed using the LACVP** basis set with a PBF solvation model56 for 
water using geometries from M06/LACVP*. C2 symmetry was used in all complexes where applicable.
Statistics. IC50-values and EC50-values (inhibitory/effective concentration 50%) were calculated by using 
non-linear regression and a standard sigmoidal dose-response model in the GraphPad Prism program (GraphPad 
Software, Inc. San Diego, CA, USA). Statistical significance was assessed using Student’s t-test (Microsoft Excel).
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